Amgen (AMGN)
(Delayed Data from NSDQ)
$333.83 USD
+2.82 (0.85%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $332.11 -1.72 (-0.52%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$333.83 USD
+2.82 (0.85%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $332.11 -1.72 (-0.52%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Amgen (AMGN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $247.09, marking a +0.05% move from the previous day.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study
by Zacks Equity Research
Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.
Amgen (AMGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $247.42, marking a +0.88% move from the previous day.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $246.73, moving +0.48% from the previous trading session.
Is Most-Watched Stock Amgen Inc. (AMGN) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Amgen (AMGN) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $243.51, marking a -0.55% move from the previous day.
Amgen (AMGN) Stock Moves -0.21%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $244.85, moving -0.21% from the previous trading session.
Radius (RDUS) to Go Private With $890M Deal, Shares Gain
by Zacks Equity Research
Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.
Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug
by Zacks Equity Research
Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.
AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention
by Zacks Equity Research
With the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only CGRP receptor antagonist approved for a broad preventive treatment of migraine indication.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $234.72, marking a +1.74% move from the previous day.
The Zacks Analyst Blog Highlights Microsoft, Amgen, Honeywell International, Booking Holdings and Stryker
by Zacks Equity Research
Microsoft, Amgen, Honeywell International, Booking Holdings and Stryker have been included in this Analyst Blog.
Amgen (AMGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $235.70, marking a -0.45% move from the previous day.
Top Research Reports for Microsoft, Amgen & Honeywell
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amgen Inc. (AMGN), and Honeywell International Inc. (HON).
Amgen (AMGN) Stock Moves -0.38%: What You Should Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $245.48, moving -0.38% from the previous trading session.
Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib
by Zacks Equity Research
Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.
Editas (EDIT) Down 20.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Radius (RDUS) to Stop Work on Abaloparatide Transdermal System
by Zacks Equity Research
Radius Health (RDUS) will pause all work on the abaloparatide transdermal system based on regulatory clarity, timeline and costs.
Why Is Blueprint Medicines (BPMC) Down 11.4% Since Last Earnings Report?
by Zacks Equity Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP